Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Jefferies downgrades Harmony Biosciences to Hold, sees limited near-term upside » 08:48
08/03/22
08/03
08:48
08/03/22
08:48
HRMY

Harmony Biosciences

$55.40 /

+6.09 (+12.35%)

As previously reported,…

As previously reported, Jefferies analyst Chris Howerton downgraded Harmony Biosciences to Hold from Buy with an unchanged price target of $57. While he "strongly" believes the company will continue to deliver on Wakix's growth trajectory following "Q2's big beat," he sees limited near-term upside and expects the stock to be range-bound until the next major clinical catalyst.

ShowHide Related Items >><<
HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

08/03/22 Oppenheimer
Harmony Biosciences price target raised to $67 from $62 at Oppenheimer
08/03/22 Jefferies
Harmony Biosciences downgraded to Hold from Buy at Jefferies
07/12/22 Goldman Sachs
Harmony Biosciences downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Harmony Biosciences initiated with a Buy at Mizuho
HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

Recommendations
Harmony Biosciences price target raised to $67 from $62 at Oppenheimer » 06:18
08/03/22
08/03
06:18
08/03/22
06:18
HRMY

Harmony Biosciences

$55.40 /

+6.09 (+12.35%)

Oppenheimer analyst…

Oppenheimer analyst Francois Brisebois raised the firm's price target on Harmony Biosciences to $67 from $62 and keeps an Outperform rating on the shares. The analyst notes the company reported Q2 results, with sales coming in at $107M and beating his estimate of $96.9M and consensus estimate of $100.7M, due to the increase in the average number of patients and smaller discounting. While Brisebois is "encouraged" by growing WAKIX demand, management expects regular seasonality in Q3. The analyst is "also encouraged" by the Bioprojet agreement to develop innovative therapeutics in narcolepsy.

ShowHide Related Items >><<
HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

08/03/22 Jefferies
Harmony Biosciences downgraded to Hold from Buy at Jefferies
07/12/22 Goldman Sachs
Harmony Biosciences downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Harmony Biosciences initiated with a Buy at Mizuho
06/29/22 Oppenheimer
Harmony Biosciences price target raised to $62 from $55 at Oppenheimer
HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

Downgrade
Harmony Biosciences downgraded to Hold from Buy at Jefferies » 05:06
08/03/22
08/03
05:06
08/03/22
05:06
HRMY

Harmony Biosciences

$55.40 /

+6.09 (+12.35%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton downgraded Harmony Biosciences to Hold from Buy with an unchanged price target of $57.

ShowHide Related Items >><<
HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

07/12/22 Goldman Sachs
Harmony Biosciences downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Harmony Biosciences initiated with a Buy at Mizuho
06/29/22 Oppenheimer
Harmony Biosciences price target raised to $62 from $55 at Oppenheimer
04/14/22 Cantor Fitzgerald
Harmony Biosciences initiated with an Overweight at Cantor Fitzgerald
HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

HRMY Harmony Biosciences
$55.40 /

+6.09 (+12.35%)

Earnings
Harmony Biosciences reports Q2 adjusted EPS 57c, consensus 44c » 07:34
08/02/22
08/02
07:34
08/02/22
07:34
HRMY

Harmony Biosciences

$49.31 /

-1.45 (-2.86%)

Reports Q2 revenue…

Reports Q2 revenue $107.028M, consensus $100.75M. "Our continued momentum helped deliver another quarter of strong growth in both WAKIX net revenue and average number of patients on WAKIX. The second quarter represented our best quarter of performance in top line prescription demand in over two years," stated John C. Jacobs, President and Chief Executive Officer of Harmony. "In addition, we are excited to announce our new agreement with Bioprojet, designed to leverage its drug discovery capabilities in combination with our proven commercial expertise in the U.S. market to develop innovative therapeutics based on pitolisant. If successful, these efforts could expand our franchise in narcolepsy by yielding one or more new products with the potential to launch during the WAKIX lifecycle."

ShowHide Related Items >><<
HRMY Harmony Biosciences
$49.31 /

-1.45 (-2.86%)

HRMY Harmony Biosciences
$49.31 /

-1.45 (-2.86%)

07/12/22 Goldman Sachs
Harmony Biosciences downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Harmony Biosciences initiated with a Buy at Mizuho
06/29/22 Oppenheimer
Harmony Biosciences price target raised to $62 from $55 at Oppenheimer
04/14/22 Cantor Fitzgerald
Harmony Biosciences initiated with an Overweight at Cantor Fitzgerald
HRMY Harmony Biosciences
$49.31 /

-1.45 (-2.86%)

HRMY Harmony Biosciences
$49.31 /

-1.45 (-2.86%)

On The Fly
Fly Insider: Stitch Fix, Arcutis Bio among week's notable insider trades » 15:52
07/18/22
07/18
15:52
07/18/22
15:52
GOSS

Gossamer Bio

$11.31 /

+0.25 (+2.26%)

, VOXX

Voxx

$7.15 /

+0.05 (+0.70%)

, SFIX

Stitch Fix

$5.93 /

+0.37 (+6.65%)

, KDP

Keurig Dr Pepper

$36.25 /

-0.38 (-1.04%)

, ABNB

Airbnb

$97.31 /

+2.66 (+2.81%)

, CRNX

Crinetics

$19.43 /

-1.55 (-7.39%)

, HRMY

Harmony Biosciences

$52.46 /

-1.21 (-2.25%)

, ARQT

Arcutis Biotherapeutics

$23.70 /

-0.51 (-2.11%)

Welcome to "Fly Insider,"…

ShowHide Related Items >><<
VOXX Voxx
$7.15 /

+0.05 (+0.70%)

SFIX Stitch Fix
$5.93 /

+0.37 (+6.65%)

KDP Keurig Dr Pepper
$36.25 /

-0.38 (-1.04%)

HRMY Harmony Biosciences
$52.46 /

-1.21 (-2.25%)

GOSS Gossamer Bio
$11.31 /

+0.25 (+2.26%)

CRNX Crinetics
$19.43 /

-1.55 (-7.39%)

ARQT Arcutis Biotherapeutics
$23.70 /

-0.51 (-2.11%)

ABNB Airbnb
$97.31 /

+2.66 (+2.81%)

GOSS Gossamer Bio
$11.31 /

+0.25 (+2.26%)

07/13/22 Piper Sandler
Gossamer private placement with 'strong investors' raises Piper's conviction
04/26/22 Barclays
Gossamer Bio price target lowered to $12 from $18 at Barclays
04/26/22 H.C. Wainwright
Gossamer Bio price target lowered to $20 from $25 at H.C. Wainwright
04/25/22 Piper Sandler
Gossamer Bio price target lowered to $15 from $26 at Piper Sandler
VOXX Voxx
$7.15 /

+0.05 (+0.70%)

07/13/22 DA Davidson
Voxx price target lowered to $16 from $20 at DA Davidson
11/08/21 Imperial Capital
Voxx initiated with an Outperform at Imperial Capital
SFIX Stitch Fix
$5.93 /

+0.37 (+6.65%)

06/28/22 Stifel
Stitch Fix price target lowered to $7 from $9 at Stifel
06/17/22 Canaccord
Stitch Fix price target lowered to $12 from $15 at Canaccord
06/13/22 Baird
Stitch Fix price target lowered to $7 from $11 at Baird
06/10/22 Truist
Stitch Fix price target lowered to $8 from $12 at Truist
KDP Keurig Dr Pepper
$36.25 /

-0.38 (-1.04%)

06/21/22 UBS
Keurig Dr Pepper downgraded to Neutral from Buy at UBS
03/22/22 Truist
Truist cuts Keurig Dr Pepper to Hold on slowdown in coffee segment post-pandemic
03/22/22 Truist
Keurig Dr Pepper downgraded to Hold from Buy at Truist
10/04/21 JPMorgan
Keurig Dr Pepper should be bought on weakness, says JPMorgan
ABNB Airbnb
$97.31 /

+2.66 (+2.81%)

07/14/22 Truist
Airbnb price target lowered to $120 from $160 at Truist
07/14/22 Citi
Airbnb price target lowered to $160 from $200 at Citi
07/07/22 Evercore ISI
Airbnb price target lowered to $150 from $205 at Evercore ISI
06/29/22 JPMorgan
Airbnb price target lowered to $110 from $185 at JPMorgan
CRNX Crinetics
$19.43 /

-1.55 (-7.39%)

06/15/22 Evercore ISI
Crinetics added to Best SMID 'Core' Ideas list at Evercore ISI
11/30/21 JMP Securities
Crinetics initiated with an Outperform at JMP Securities
11/23/21 Evercore ISI
Evercore starts 'rare endo treasure trove' Crinetics at Outperform
11/23/21 Evercore ISI
Crinetics initiated with an Outperform at Evercore ISI
HRMY Harmony Biosciences
$52.46 /

-1.21 (-2.25%)

07/12/22 Goldman Sachs
Harmony Biosciences downgraded to Neutral from Buy at Goldman Sachs
07/06/22 Mizuho
Harmony Biosciences initiated with a Buy at Mizuho
06/29/22 Oppenheimer
Harmony Biosciences price target raised to $62 from $55 at Oppenheimer
04/14/22 Cantor Fitzgerald
Harmony Biosciences initiated with an Overweight at Cantor Fitzgerald
ARQT Arcutis Biotherapeutics
$23.70 /

-0.51 (-2.11%)

06/28/22 Mizuho
Arcutis shares have 'significantly more upside,' says Mizuho
05/26/22 Mizuho
Arcutis Biotherapeutics selloff a buying opportunity, says Mizuho
04/07/22 Mizuho
Arcutis Biotherapeutics price target lowered to $57 from $58 at Mizuho
03/17/22 Goldman Sachs
Arcutis Biotherapeutics initiated with a Buy at Goldman Sachs
VOXX Voxx
$7.15 /

+0.05 (+0.70%)

SFIX Stitch Fix
$5.93 /

+0.37 (+6.65%)

KDP Keurig Dr Pepper
$36.25 /

-0.38 (-1.04%)

HRMY Harmony Biosciences
$52.46 /

-1.21 (-2.25%)

GOSS Gossamer Bio
$11.31 /

+0.25 (+2.26%)

CRNX Crinetics
$19.43 /

-1.55 (-7.39%)

ARQT Arcutis Biotherapeutics
$23.70 /

-0.51 (-2.11%)

ABNB Airbnb
$97.31 /

+2.66 (+2.81%)

  • 13
    Apr
  • 21
    Oct
SFIX Stitch Fix
$5.93 /

+0.37 (+6.65%)

KDP Keurig Dr Pepper
$36.25 /

-0.38 (-1.04%)

ABNB Airbnb
$97.31 /

+2.66 (+2.81%)

VOXX Voxx
$7.15 /

+0.05 (+0.70%)

SFIX Stitch Fix
$5.93 /

+0.37 (+6.65%)

KDP Keurig Dr Pepper
$36.25 /

-0.38 (-1.04%)

GOSS Gossamer Bio
$11.31 /

+0.25 (+2.26%)

ARQT Arcutis Biotherapeutics
$23.70 /

-0.51 (-2.11%)

ABNB Airbnb
$97.31 /

+2.66 (+2.81%)

SFIX Stitch Fix
$5.93 /

+0.37 (+6.65%)

KDP Keurig Dr Pepper
$36.25 /

-0.38 (-1.04%)

ABNB Airbnb
$97.31 /

+2.66 (+2.81%)

Over a month ago
Downgrade
Harmony Biosciences downgraded to Neutral from Buy at Goldman Sachs » 16:39
07/12/22
07/12
16:39
07/12/22
16:39
HRMY

Harmony Biosciences

$54.30 /

-0.42 (-0.77%)

Goldman Sachs analyst…

Goldman Sachs analyst Corinne Jenkins downgraded Harmony Biosciences to Neutral from Buy with a $55 price target. The stock has risen 85% since being added to the firm's Americas Buy List in March of 2021, and its valuation now reflects the market opportunity for Wakix in narcolepsy and key expansion indications, the analyst tells investors in a research note. Jenkins adds that Harmony's cash flow generation puts the company in strong position to execute business development and extend its revenue durability beyond the Wakix loss of exclusivity in 2029.

ShowHide Related Items >><<
HRMY Harmony Biosciences
$54.30 /

-0.42 (-0.77%)

HRMY Harmony Biosciences
$54.30 /

-0.42 (-0.77%)

07/06/22 Mizuho
Harmony Biosciences initiated with a Buy at Mizuho
06/29/22 Oppenheimer
Harmony Biosciences price target raised to $62 from $55 at Oppenheimer
04/14/22 Cantor Fitzgerald
Harmony Biosciences initiated with an Overweight at Cantor Fitzgerald
11/30/21 Oppenheimer
Harmony Biosciences initiated with an Outperform at Oppenheimer
HRMY Harmony Biosciences
$54.30 /

-0.42 (-0.77%)

Initiation
Harmony Biosciences initiated with a Buy at Mizuho » 16:10
07/06/22
07/06
16:10
07/06/22
16:10
HRMY

Harmony Biosciences

$54.90 /

+2.32 (+4.41%)

Mizuho analyst Graig…

Mizuho analyst Graig Suvannavejh initiated coverage of Harmony Biosciences with a Buy rating and $64 price target. The analyst favors Harmony for its "strong fundamentals," which he says includes favorable growth prospects for its lead asset Wakix as well as a "revenue-generating, already profitable" portfolio. Suvannavejh views Harmony as a "compelling, de-risked story."

ShowHide Related Items >><<
HRMY Harmony Biosciences
$54.90 /

+2.32 (+4.41%)

HRMY Harmony Biosciences
$54.90 /

+2.32 (+4.41%)

06/29/22 Oppenheimer
Harmony Biosciences price target raised to $62 from $55 at Oppenheimer
04/14/22 Cantor Fitzgerald
Harmony Biosciences initiated with an Overweight at Cantor Fitzgerald
11/30/21 Oppenheimer
Harmony Biosciences initiated with an Outperform at Oppenheimer
11/04/21
Fly Intel: Top five analyst initiations
HRMY Harmony Biosciences
$54.90 /

+2.32 (+4.41%)

Recommendations
Harmony Biosciences price target raised to $62 from $55 at Oppenheimer » 06:39
06/29/22
06/29
06:39
06/29/22
06:39
HRMY

Harmony Biosciences

$50.66 /

-1.52 (-2.91%)

Oppenheimer analyst…

Oppenheimer analyst Francois Brisebois raised the firm's price target on Harmony Biosciences to $62 from $55 and keeps an Outperform rating on the shares after spending the day with management and coming away "incrementally more positive." Despite market conditions, Harmony's 1-year chart is up over 80%, the analyst notes. Following its recent pullback related to reimbursement challenges in Q1, Brisebois believes strong fundamentals and increasing organic demand have led to a strong rebound. Furthermore, the analyst thinks M&A is very much on the table, especially given the market downturn, Harmony's profitability and its cash.

ShowHide Related Items >><<
HRMY Harmony Biosciences
$50.66 /

-1.52 (-2.91%)

HRMY Harmony Biosciences
$50.66 /

-1.52 (-2.91%)

04/14/22 Cantor Fitzgerald
Harmony Biosciences initiated with an Overweight at Cantor Fitzgerald
11/30/21 Oppenheimer
Harmony Biosciences initiated with an Outperform at Oppenheimer
11/04/21
Fly Intel: Top five analyst initiations
11/03/21 Raymond James
Harmony Biosciences initiated with an Outperform at Raymond James
HRMY Harmony Biosciences
$50.66 /

-1.52 (-2.91%)

Hot Stocks
Harmony Biosciences director sells $5.26M in common stock » 18:36
06/28/22
06/28
18:36
06/28/22
18:36
HRMY

Harmony Biosciences

$50.66 /

-1.52 (-2.91%)

In a regulatory filing,…

In a regulatory filing, Harmony Biosciences disclosed that its director Jack Nielson sold 100.5K shares of common stock on June 24th in a total transaction size of $5.26M.

ShowHide Related Items >><<
HRMY Harmony Biosciences
$50.66 /

-1.52 (-2.91%)

HRMY Harmony Biosciences
$50.66 /

-1.52 (-2.91%)

04/14/22 Cantor Fitzgerald
Harmony Biosciences initiated with an Overweight at Cantor Fitzgerald
11/30/21 Oppenheimer
Harmony Biosciences initiated with an Outperform at Oppenheimer
11/04/21
Fly Intel: Top five analyst initiations
11/03/21 Raymond James
Harmony Biosciences initiated with an Outperform at Raymond James
HRMY Harmony Biosciences
$50.66 /

-1.52 (-2.91%)

Conference/Events
Harmony Biosciences management to meet with Oppenheimer » 04:55
06/27/22
06/27
04:55
06/27/22
04:55
HRMY

Harmony Biosciences

$51.71 /

+0.49 (+0.96%)

Meeting to be held on…

Meeting to be held on June 27 hosted by Oppenheimer.

ShowHide Related Items >><<
HRMY Harmony Biosciences
$51.71 /

+0.49 (+0.96%)

HRMY Harmony Biosciences
$51.71 /

+0.49 (+0.96%)

04/14/22 Cantor Fitzgerald
Harmony Biosciences initiated with an Overweight at Cantor Fitzgerald
11/30/21 Oppenheimer
Harmony Biosciences initiated with an Outperform at Oppenheimer
11/04/21
Fly Intel: Top five analyst initiations
11/03/21 Raymond James
Harmony Biosciences initiated with an Outperform at Raymond James
HRMY Harmony Biosciences
$51.71 /

+0.49 (+0.96%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.